Advertisement

Drug Safety

pp 1–7 | Cite as

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study

  • Adi J. Klil-Drori
  • Christina Santella
  • Koray Tascilar
  • Hui Yin
  • Armen Aprikian
  • Laurent AzoulayEmail author
Original Research Article

Abstract

Introduction

Two recent observational studies have investigated the association between androgen deprivation therapy (ADT) and rheumatoid arthritis (RA), but generated discrepant findings and had important methodological limitations. Thus, the objective of this study was to determine whether the use of ADT is associated with an increased risk of RA in men with prostate cancer.

Patients and Methods

We conducted a population-based cohort study using the United Kingdom Clinical Practice Research Datalink. The cohort included all men, at least 40 years of age, newly diagnosed with prostate cancer between 1 January 1988 and 31 March 2014, with follow-up until 30 September 2014. Exposure to ADT was treated as a time-varying variable and lagged by 1 year to account for diagnostic delays and latency. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of RA, comparing use of ADT with non-use. Secondary analyses were conducted to assess whether the association varied according to ADT type and cumulative duration of use. Finally, we conducted several sensitivity analyses to assess the robustness of our findings.

Results

The cohort included 32,302 men followed for a median of 3.3 years. During follow-up, 63 patients were newly diagnosed with RA, generating an incidence rate of 46.5/100,000 person-years. Compared with non-use, the use of ADT was not associated with an increased risk of RA (HR 0.84, 95% CI 0.49–1.45). In secondary analyses, the association did not vary according to ADT type or with cumulative duration of use (p trend = 0.53). The results remained consistent in sensitivity analyses.

Conclusion

In this population-based study, the use of ADT was not associated with an increased risk of RA in men with prostate cancer.

Notes

Compliance with Ethical Standards

Funding

This study was funded by a Foundation Scheme Grant from the Canadian Institutes of Health Research. Dr Laurent Azoulay holds a Chercheur-Boursier Senior Award from the Fonds de la Recherche du Québec – Santé and is the recipient of a William Dawson Scholar Award from McGill University.

Conflict of interest

The funding source had no role in the design, analysis, or interpretation of the results. Adi Klil-Drori, Christina Santella, Koray Tascilar, Hui Yin, Armen Aprikian, and Laurent Azoulay have no conflicts of interest that are directly relevant to the content of this study.

Ethical approval

The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD [protocol number 14_228A] and the Research Ethics Committee of the Jewish General Hospital, Montreal, Canada.

Supplementary material

40264_2019_847_MOESM1_ESM.pdf (87 kb)
Supplementary material 1 (PDF 87 kb)

References

  1. 1.
    Bekelman JE, Mitra N, Handorf EA, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol. 2015;33:716.CrossRefGoogle Scholar
  2. 2.
    Klil-Drori AJ, Tascilar K, Yin H, et al. Androgen deprivation therapy and the incidence of inflammatory bowel disease in patients with prostate cancer. Am J Epidemiol. 2016;184:15–22.CrossRefGoogle Scholar
  3. 3.
    Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73:1316–22.CrossRefGoogle Scholar
  4. 4.
    Heikkila R, Aho K, Heliovaara M, et al. Serum androgen-anabolic hormones and the risk of rheumatoid arthritis. Ann Rheum Dis. 1998;57:281–5.CrossRefGoogle Scholar
  5. 5.
    Masi AT, Rehman AA, Chatterton RT, et al. Controlled cohort study of serum gonadal and adrenocortical steroid levels in males prior to onset of rheumatoid arthritis (pre-RA): a comparison to pre-RA females and sex differences among the study groups. Int J Rheumatol. 2013;2013:284145.CrossRefGoogle Scholar
  6. 6.
    Pikwer M, Giwercman A, Bergstrom U, et al. Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study. Ann Rheum Dis. 2014;73:573–9.CrossRefGoogle Scholar
  7. 7.
    Cutolo M, Balleari E, Giusti M, et al. Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1–5.CrossRefGoogle Scholar
  8. 8.
    Hall GM, Larbre JP, Spector TD, et al. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol. 1996;35:568–73.CrossRefGoogle Scholar
  9. 9.
    Kass AS, Forre OT, Fagerland MW, et al. Short-term treatment with a gonadotropin-releasing hormone antagonist, cetrorelix, in rheumatoid arthritis (AGRA): a randomized, double-blind, placebo-controlled study. Scand J Rheumatol. 2014;43:22–7.CrossRefGoogle Scholar
  10. 10.
    Kass A, Hollan I, Fagerland MW, et al. Rapid anti-inflammatory effects of gonadotropin-releasing hormone antagonism in rheumatoid arthritis patients with high gonadotropin levels in the AGRA trial. PLoS One. 2015;10:e0139439.CrossRefGoogle Scholar
  11. 11.
    Pope JE, Joneja M, Hong P. Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis. J Rheumatol. 2002;29:2459–62.Google Scholar
  12. 12.
    Yang DD, Krasnova A, Nead KT, et al. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Ann Oncol. 2018;29:386–91.CrossRefGoogle Scholar
  13. 13.
    Liu J-M, Yu C-P, Chuang H-C, et al. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Prostate Cancer Prostatic Dis. 2019.  https://doi.org/10.1038/s41391-019-0130-9.Google Scholar
  14. 14.
    Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827–36.CrossRefGoogle Scholar
  15. 15.
    Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69:4–14.CrossRefGoogle Scholar
  16. 16.
    Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the general practice research database: a systematic review. Br J Gen Pract. 2010;60:e128–36.CrossRefGoogle Scholar
  17. 17.
    van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum. 2010;62:3537–46.CrossRefGoogle Scholar
  18. 18.
    Thomas SL, Edwards CJ, Smeeth L, et al. How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum. 2008;59:1314–21.CrossRefGoogle Scholar
  19. 19.
    Muller S, Hider SL, Raza K, et al. An algorithm to identify rheumatoid arthritis in primary care: a Clinical practice research datalink study. BMJ Open. 2015;5:e009309.CrossRefGoogle Scholar
  20. 20.
    Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075–9 (discussion 1081–1090).CrossRefGoogle Scholar
  21. 21.
    de Hair MJ, Landewe RB, van de Sande MG, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis. 2013;72:1654–8.CrossRefGoogle Scholar
  22. 22.
    Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case–control study in Norfolk, England. Arthritis Rheum. 1997;40:1955–61.CrossRefGoogle Scholar
  23. 23.
    Nicholson A, Ford E, Davies KA, et al. Optimising use of electronic health records to describe the presentation of rheumatoid arthritis in primary care: a strategy for developing code lists. PLoS One. 2013;8:e54878.CrossRefGoogle Scholar
  24. 24.
    Somers EC, Thomas SL, Smeeth L, Hall AJ. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169:749–55.CrossRefGoogle Scholar
  25. 25.
    Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30:2768–75.CrossRefGoogle Scholar
  26. 26.
    Humphreys JH, Verstappen SM, Hyrich KL, et al. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2013;72:1315–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Adi J. Klil-Drori
    • 1
  • Christina Santella
    • 1
    • 3
  • Koray Tascilar
    • 1
    • 4
  • Hui Yin
    • 1
  • Armen Aprikian
    • 5
  • Laurent Azoulay
    • 1
    • 2
    • 3
    Email author
  1. 1.Center for Clinical Epidemiology, Jewish General HospitalLady Davis InstituteMontrealCanada
  2. 2.Gerald Bronfman Department of OncologyMcGill UniversityMontrealCanada
  3. 3.Department of Epidemiology, Biostatistics, and Occupational HealthMcGill UniversityMontrealCanada
  4. 4.Department of Internal MedicineUniversitätsklinikum ErlangenErlangenGermany
  5. 5.McGill University Health CentreMcGill UniversityMontrealCanada

Personalised recommendations